Rafael Holdings, Inc. (RFL) Stock

Rafael Holdings, Inc. (RFL) is a Healthcare stock trading at $2.15 (as of 2026-08-21), with a market capitalization of $109.89M. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.

Rafael Holdings, Inc. invests in clinical-stage and early-stage pharmaceutical companies and holds commercial real estate assets in the United States and Israel. It operates through Pharmaceuticals and Real Estate segments, including leasing a commercial office building with an attached public garage and developing and commercializing therapies based on metabolic differences between normal and cancer cells, with CPI-613 (devimistat) in clinical trials.

Understand Rafael Holdings, Inc.: how it makes money

Rafael Holdings owns commercial real estate (including a leased office building and an associated 800-car public garage) and develops and commercializes oncology therapies, centered on CPI-613 (devimistat).

The profit model is a mix of Real Estate leasing and Pharmaceuticals development, meaning outcomes depend on ongoing clinical progress for CPI-613 and the ability to convert that progress into commercially valuable therapies, while the Real Estate side is driven by leasing assets.

Business quality (Weak): Two-segment structure (Real Estate and Pharmaceuticals) with operating momentum tied to CPI-613 trial progress, but the company also reports no revenue for the latest period and an extremely negative operating margin as provided.

Bull case

  • Real Estate segment provides a defined business activity: The company leases a commercial office building and an associated 800-car public garage through its Real Estate segment.
  • Pivotal Phase 3 trial progress metrics are tracked: The operational view includes Pivotal Phase 3 TransportNPC study activity, including Patients Studied (94) and Study Sites (27), plus a Pediatric Sub-Study enrollment metric (10) and a Clinical Global Impression metric showing improvements or remaining stable (80%).

Bear case

  • Pharmaceuticals value depends on clinical and commercialization outcomes: The lead drug candidate, CPI-613 (devimistat), is being evaluated in multiple clinical studies, and the Pharmaceuticals segment relies on continued progress toward commercialization.
  • Latest reported financials show no revenue and major losses as provided: For the period ended 2026-04-30, reported revenue is 0.0B and operating margin is -3838.0 (as provided).
Valuation — source: SEC EDGAR (first-party)
Price$2.15
Market Cap$109.89M
Price / Book1.36
Price / Sales112.13
FCF Yield-22.9%
Profitability & Growth — source: SEC EDGAR
Revenue (TTM)$917000.00
Net Margin-3328.2%
Revenue Growth (YoY)-50.6%
EPS Growth (YoY)-57.9%
FCF Growth (YoY)128.4%
Financial Health — source: SEC EDGAR
Altman Z-Score-0.80 (distress)
Valuation vs Sector & Industry
Sector P/E (Healthcare)21.7
Industry P/E (Pharmaceutical Products)17.0
Smart-Money Activity — SEC Form 4 / 13F / Congressional disclosures
Top Institutional HolderVANGUARD GROUP INC ($1.76M)
Institutional Holders Tracked10
Company
SectorHealthcare
IndustryPharmaceutical Products
CEOHoward S. Jonas
Employees28
CountryUS
IPO Date2018-03-27

Related Companies (Business model: Biotech (Clinical / Commercial-Stage); 8 closest by market cap; US-domiciled)

  • Anixa Biosciences, Inc. (ANIX)
  • Genelux Corporation (GNLX)
  • Inovio Pharmaceuticals, Inc. (INO)
  • Neonc Technologies Holdings, Inc. (NTHI)
  • Cumberland Pharmaceuticals Inc. (CPIX)
  • Coya Therapeutics, Inc. (COYA)
  • Polaryx Therapeutics, Inc. Common Stock (PLYX)
  • Biomea Fusion, Inc. (BMEA)
RFL earnings history · RFL institutional & insider holders · RFL KPIs & operating metrics · RFL financials · RFL investor presentations & press releases · RFL SEC filings · RFL peers · Congress trades · Insider trades · Short interest · Stock screener

Data as of 2026-08-21.

Figures sourced from U.S. Securities and Exchange Commission (SEC EDGAR) filings and market data. Not personalized investment advice.